Sat, Oct 25, 2014, 11:34 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • neshua10 neshua10 Nov 5, 2013 10:06 PM Flag

    Really? result may not be good as expected! Oh Really? Tell me more!

    "The results in the 25 initial patients will be reported at the Society for Neuro-Oncology Annual Meeting of November 21 through 24 in San Francisco. The embargo on the abstract will be lifted on Monday, November 11, and available on the SNO website. It has been accepted as an oral presentation and is entitled "ReACT: a Phase 2 Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma." The oral presentation will be made in a session lasting from 10:20 AM to 12:00 PM on Sunday, November 24. On Monday, November 25, at 8:30 am EST, management will also hold a conference call to review the data."

    Now, now, now, let's see shall we? They are being invited among a handful rare to give an oral presentation of the data results on1127. I can only imagine, can you picture it? "Results are poor to at very best fair. We thought you dear oncologists in the audience needed a laugh. And to further the ante of kicking ourselves down the drain we thought it best 24 hours henceforth on 11/25/13 to hold a CC to have the torch doubly lit so you may laugh harder and really short the hell out of us!" WAKE THE h-- ll up! SO many are lemmings on way or another with attention/retention span of fleas!!!!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CLDX
15.50+0.09(+0.58%)Oct 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.